Hyperprolactinemia inhibits natural killer (NK) cell functionin vivo and its bromocriptine treatment not only corrects it but makes it more efficient
Tóm tắt
We studied NK cell function in eight patients with pathological hyperprolactinemia by measuring51Cr release by K562 cells exposed to their mononuclear cells and found it decreased compared to normal controls (P<0.01). Bromocriptine (BrC) treatment corrected NK function but also made it more efficient at 12:1 than at 25:1 or 50:1 effector:target ratios (ANOVA;P=0.01). The study of NK cell function in agarose revealed that its decrease in hyperprolactinemia is due to their low active binding to target cells, active killing, and recycling capacity. BrC tended to correct them but also increased recycling capacity to levels higher than those of controls (P<0.05). Sequential studies in three hyperprolactinemic patients before and after BrC showed correction of NK function within 1 week but its increased efficiency at the 12:1 effector:target ratio required 8 weeks. We conclude that hyperprolactinemia decreases NK cell function. BrC corrects this by decreasing prolactin levels but also makes NK function more efficient by increasing the capacity of NK cells to recycle after killing.
Tài liệu tham khảo
Nagy E, Berczi I: Immunodeficiency in hypophysectomized rats. Acta Endocrinol 89:530–537, 1978
Berczi I, Nagy E, Kovacs K, Horvath E: Regulation of humoral immunity in rats by pituitary hormones. Acta Endocrinol 98:506–513, 1983
Nagy E, Berczi I, Friesen HG: Regulation of immunity in rats by lactogenic & growth hormones. Acta Endocrinol 102:351–357, 1983
Russell DH, Kibler R, Matrisian L, Larson DF, Poulos B, Magun BE: Prolactin receptors on human T and B lymphocytes: antagonism of prolactin binding by cyclosporin. J Immunol 134:3027–3031, 1985
Vidaller A, LLorente L, Larrea F, Mendez JP, Alcocer-Varela J, Alarcon-Segovia D: T cell dysregulation in patients with hyperprolactinemia: Effect of bromocriptine treatment. Clin Immunol Immunopathol 38:337–343, 1985
Gerli C, Riccardi C, Nicoletti I, Orlandi S, Cernetti C, Spinozzi F, Rambotti P: Phenotypic and functional abnormalities of T lymphocytes in pathological hyperprolactinemia. J Clin Immunol 7:463–470, 1987
Gerli C, Rambotti P, Nicoletti I, Orlandi S, Migliorati G, Riccardi C: Reduced number of natural killer cells in patients with pathological hyperprolactinemia. Clin Exp Immunol 64:399–406, 1986
Matera L, Ciccarelli E, Cesano A, Veglia F, Miola C, Camanni F: Natural killer activity in hyperprolactinemic patients. Immunopharmacology 18:143–146, 1989
Grabstein K: Cell mediated cytolytic responses.In Selected Methods in Cellular Immunology, BB Mishell, SM Shiligi (eds). San Francisco, WH Freeman, 1980, pp 124–137
Grimm E, Bonavida B: Mechanism of cell-mediated cytotoxicity at the single cell level. I. Estimation of cytotoxic T lymphocyte frequency and relative lytic efficiency. J Immunol 123:2861–2869, 1989
Ulberg M, Jondal M: Recycling and target binding capacity of human natural killer cells. J Exp Med 153:615–628, 1981
Carrier MC, Wild J, Pelletier JC, Copeland JG: Bromocriptine as an adjuvant to cyclosporin immunosuppression after heart transplantation. Ann Thorac Surg 49:129–132, 1990
Palestine AG, Muellenberg-Coulombre CG, Kim MK, Gelato MC, Nussenblatt RB: Bromocriptine and low dose cyclosporine in the treatment of experimental autoimmune uveitis in the rat. J Clin Invest 79:1078–1081, 1987
Blank M, Palestine A. Nussenblatt R, Shoenfeld Y: Downregulation of autoantibody levels of cyclosporine and bromocriptine treatment in patients with uveitis. Clin Immunol Immunopathol 54:87–97, 1990
Rios EP, Herrera J, Bermudez JA, Rocha G, Lisker R, Morato T, Perez-Palacios G: Endocrine and metabolic studies in an XY patient with gonadal agenesis. J Clin Endocrinol Metab 39:540–545, 1974
Böyum A: Isolation of mononuclear cells and granulocytes from human blood. Scand J Clin Lab Invest 21 (Suppl 97):77–98, 1968
Gonzalez-Amaro R, Alcocer-Varela J, Martinez-Cordero E, Alarcon-Segovia D: Natural killer cell-mediated activity in mixed connective tissue disease and its response to induction by interleukin-2. J Clin Immunol 4:273–279, 1984
Katz P, Zaytonn AM, Lee JH, Panush R, Langley S: Abnormal natural killer cell activity in systemic lupus erythematosus. An intrinsic defect in the lytic event. J Immunol 129:1966–1971, 1982
Kabat EA, Mayer MM: Experimental Immunochemistry. Springfield, IL, Thomas, 1961
Hiestand PC, Meckler P, Nordmann R, Grieder A, Permmongkol C: Prolactin as a modulator of lymphocyte responsiveness provides a possible mechanism of action for cyclosporine. Proc Natl Acad Sci USA 83:2599–2603, 1986
Nagy E, Berczi I, Wren GE, Asa SL, Kovacs K: Immunomodulation by bromocriptine. Immunopharmacology 6:231–243, 1983
Hedner LP, Bynke G: Endogenous iridocyclitis relieved during treatment with bromocriptine. Am J Ophthalmol 100:618–619, 1985